Polymorphonuclear neutrophils from JAK2V617F positive MPD patients do not support hypercoagulability: A study with calibrated automated thrombography (CAT)

Blood Cells, Molecules, and Diseases

Volumn 46, Issue 3, 2011, Pages 235-238

  Perrin, Julien ^a,b,c   Ranta, Dana ^a,b   Empereur, Fabienne ^a,b   Vigneron, Claude ^a,b,c   Feugier, Pierre ^a,b   Lecompte, Thomas ^a,b,d  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d INSERM   (France)

Author keywords

Hypercoagulability; Myeloproliferative disorders; Polymorphonuclear neutrophils; Thrombin generation

Indexed keywords

ACTIVATED PROTEIN C; JANUS KINASE 2; THROMBIN;

ADOLESCENT; ANALYTIC METHOD; ARTICLE; BLOOD CLOTTING; CALIBRATED AUTOMATED THROMBOGRAPHY; CELLULAR DISTRIBUTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; IN VITRO STUDY; MALE; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; SCHOOL CHILD; THROMBIN TIME; ADULT; AGED; BLOOD CLOTTING TEST; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; POLYCYTHEMIA VERA; THROMBOCYTHEMIA; THROMBOPHILIA;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION TESTS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NEUTROPHILS; POLYCYTHEMIA VERA; THROMBIN; THROMBOCYTHEMIA, ESSENTIAL; THROMBOPHILIA;

EID: 79952107798     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2011.01.003     Document Type: Article

References (31)

1. De Stefano V., Za T., Rossi E., et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008, 93(3):372-380.
2. Petrides P.E., Siegel F. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles. Blood Cells Mol. Dis. 2006, 36(3):379-384.
3. Finazzi G., Rambaldi A., Guerini V., et al. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007, 92(1):135-136.
4. Wolanskyj A.P., Schwager S.M., McClure R.F., et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin. Proc. 2006, 81(2):159-166.
5. Landolfi R., Di Gennaro L., Barbui T.V., et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007, 109(6):2446-2452.
6. Carobbio A., Antonioli E., Guglielmelli P., et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J. Clin. Oncol. 2008, 26(16):2732-2736.
7. Caramazza D., Caracciolo C., Barone R., et al. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Ann. Hematol. 2009, 88(10):967-971.
8. Marchetti M., Falanga A. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders. Pathophysiol. Haemost. Thromb. 2008, 36(3-4):148-159.
9. Falanga A., Marchetti M., Evangelista V., et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000, 96(13):4261-4266.
10. Perrin J., Morlon L., Vigneron C., et al. Influence of polymorphonuclear leukocytes on the plasma clot formation as evaluated by thromboelastometry (ROTEM). Thromb. Res. 2008, 121(5):647-652.
11. Perrin J., Lecompte T., Tournier A., et al. In vitro effects of human neutrophil cathepsin G on thrombin generation: both acceleration and decreased potential. Thromb. Haemost. 2010, 104(3):514-522.
12. Hemker H.C., Giesen P., Al Dieri R., et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol. Haemost. Thromb. 2002, 32(5-6):249-253.
13. Hemker H.C., Giesen P., Al Dieri R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol. Haemost. Thromb. 2003, 33(1):4-15.
14. Chantarangkul V., Clerici M., Bressi C., et al. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 2003, 88(5):547-554.
15. Regnault V., Béguin S., Lecompte T. Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability. Pathophysiol. Haemost. Thromb. 2003, 33(1):23-29.
16. Regnault V., Hemker H.C., Wahl D., et al. Phenotyping the haemostatic system by thrombography-potential for the estimation of thrombotic risk. Thromb. Res. 2004, 114(5-6):539-545.
17. van Hylckama Vlieg A., Christiansen S.C., Luddington R., et al. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br. J. Haematol. 2007, 138(6):769-774.
18. Trossaërt M., Regnault V., Sigaud M., et al. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype. J. Thromb. Haemost. 2008, 6(3):486-493.
19. Luddington R., Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J. Thromb. Haemost. 2004, 2(11):1954-1959.
20. Habib H., Fazili K.M. Plant protease inhibitors: a defense strategy in plants. Biotechnol. Mol. Biol. Rev. 2007, 2(3):68-85.
21. Spronk H.M., Dielis A.W., Panova-Noeva M., et al. Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?. Thromb. Haemost. 2009, 101(6):1156-1162.
22. Passamonti F., Rumi E., Pietra D., et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006, 107(9):3676-3682.
23. Alvarez-Larrán A., García-Pagán J.C., Abraldes J.G., et al. Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. Br. J. Haematol. 2004, 124(3):329-335.
24. Falanga A., Marchetti M., Vignoli A., et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp. Hematol. 2007, 35(5):702-711.
25. Samuelsson J., Berg A. Further studies of defective stimulus-response coupling for the oxidative burst in neutrophils in polycythemia vera. Eur. J. Haematol. 1991, 47(4):239-245.
26. Burgaleta C., González N., César J. Increased CD11/CD18 expression and altered metabolic activity on polymorphonuclear leukocytes from patients with polycythemia vera and essential thrombocythemia. Acta Haematol. 2002, 108(1):23-28.
27. Wolach B., Gavrieli R., Manor Y., et al. Leukocyte function in chronic myeloproliferative disorders. Blood Cells Mol. Dis. 1998, 24(4):544-551.
28. Sanchez S., Ewton A. Essential thrombocythemia: a review of diagnostic and pathologic features. Arch. Pathol. Lab. Med. 2006, 130(8):1144-1150.
29. Cervantes F., Arellano-Rodrigo E., Alvarez-Larrán A. Blood cell activation in myeloproliferative neoplasms. Haematologica 2009, 94(11):1484-1488.
30. Marchetti M., Castoldi E., Spronk H.M., et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008, 112(10):4061-4068.
31. Duchemin J., Ugo V., Ianotto J.C., et al. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb. Res. 2010, 126(3):238-242.